Urine Specimens from Pregnant and Nonpregnant Women Inhibitory to Amplification of *Chlamydia trachomatis* Nucleic Acid by PCR, Ligase Chain Reaction, and Transcription-Mediated Amplification: Identification of Urinary Substances Associated with Inhibition and Removal of Inhibitory Activity

**J. MAHONY,1,2,3* S. CHONG,1 D. JANG,1 K. LUINSTRA,1 M. FAUGHT,1 D. DALBY,3 J. SELLORS,3,4 AND M. CHERNESKY1,2,3,5**

Regional Virology and Chlamydiology Laboratory,1 Departments of Pathology,2 Pediatrics,3 and Family Medicine,4 McMaster University, and FSORC, St. Joseph’s Hospital,3 Hamilton, Ontario, Canada

Received 3 April 1998/Returned for modification 29 June 1998/Accepted 7 August 1998

The presence of endogenous amplification inhibitors in urine may produce false-negative results for the detection of *Chlamydia trachomatis* nucleic acids by tests such as PCR, ligase chain reaction (LCR), and transcription-mediated amplification (TMA). Consecutive urine specimens from 101 pregnant women and 287 nonpregnant women submitted for urinalysis were processed for *C. trachomatis* detection. Aliquots were spiked with the equivalent of one *C. trachomatis* elementary body and were tested by three commercial assays: AMPLICOR CT/NG, Chlamydia LCX, and Chlamydia TMA. The prevalence of inhibitors resulting in complete inhibition of amplification was 4.9% for PCR, 2.6% for LCR, and 7.5% for TMA. In addition, all three assays were partially inhibited by additional urine specimens. Only PCR was more often inhibited by urine from pregnant women than by urine from nonpregnant women (9.9 versus 3.1%; *P* = 0.011). A complete urinalysis including dipstick and microscopic examination was performed. Logistic regression analysis revealed that the following substances were associated with amplification inhibition: beta-human chorionic gonadotropin (odds ratio [OR], 3.3) and crystals (OR, 3.3) for PCR, nitrites for LCR (OR, 14.4), and hemoglobin (OR, 3.3), nitrites (OR, 3.3), and crystals (OR, 3.3) for TMA. Aliquots of each inhibitory urine specimen were stored at 4 and −70°C overnight or were extracted with phenol-chloroform and then retested at dilutions of 1:1, 1:4, and 1:10. Most inhibition was removed by storage overnight at 4 or −70°C and a dilution of 1:10 (84% for PCR, 100% for LCR, and 92% for TMA). Five urine specimens (three for PCR and two for TMA) required phenol-chloroform extraction to remove inhibitors. The results indicate that the prevalence of nucleic acid amplification inhibitors in female urine is different for each technology, that this prevalence may be predicted by the presence of urinary factors, and that storage and dilution remove most of the inhibitors.

**MATERIALS AND METHODS**

**Specimens.** This laboratory-based study tested 388 freshly collected urine specimens submitted for routine urinalysis to clinical chemistry laboratories in three university teaching hospitals. Urine specimens (20 to 50 ml) were obtained from 101 pregnant women and 287 nonpregnant women between 15 and 40 years of age. The specimens were transported by courier at room temperature each morning, together with a printed copy of the urinalysis report, to the Regional Virology and Chlamydiology Laboratory at St. Joseph’s Hospital, aliquoted by one technologist, and tested blindly on the same day by three *C. trachomatis* nucleic acid detection assays.

**Urinalysis.** A complete urinalysis including dipstick and microscopic examination was performed for each urine specimen. Fresh urine specimens were tested for the presence of leukocytes, nitrites, protein, blood, ketone, and glucose, and their specific gravities and pHs were measured with the Multistix 8 SG dipstick (Bayer Inc., Etobicoke, Ontario, Canada). The dipstick was read, according to the manufacturer’s instructions, with an automated urine chemistry analyzer (Clinistix 200+; Bayer Corp.). Positive urine protein results from the dipstick were confirmed by a semiquantitative sulfosalicylic acid test, which simply...

Nucleic acid amplification (NAA) techniques such as PCR, ligase chain reaction (LCR), and transcription-mediated amplification (TMA) have greatly improved our ability to diagnose *Chlamydia trachomatis* infections, and in recent years, they have been successfully applied to first-void urine specimens. NAA testing of first-void urine specimens has usually detected as many positive patients as testing of urethral or endocervical swabs by cell culture or antigen testing (1–3, 5, 6, 8, 10, 12, 15), but most of these studies have also revealed that the urinary components associated with amplification inhibition; and (iii) treatment procedures which might remove inhibitors from urine.
involved the mixing of 1.0 ml of centrifuged urine to 3.0 ml of 3% sulfosalicylic acid. After 5 min, the degree of turbidity caused by the precipitation of denatured protein was observed and was graded from negative to ++. For microscopic examination of the urine, 10- to 15-ml aliquots were spun at 1,000 rpm for 5 min. A drop of the resulting sediment was transferred to a microscope slide. Examination for epithelial cells, erythrocytes and leukocytes, mucus, yeast, bacteria, casts, and various types of crystals (oxalate, phosphate, urate) was done under both low and high magnifications of the light microscope by trained technicians using standard criteria (17).

Detection of amplification inhibitors by spiking experiments. C. trachomatis L2 434 was propagated in McCoy cells, and elementary bodies (EBs) were resuspended in phosphate-buffered saline and counted by direct fluorescent-antibody (DFA) staining with monoclonal antibodies specific for major outer membrane proteins (Syva Microtrak, San Jose, Calif.). A serial dilution of antibody (DFA) staining with monoclonal antibodies specific for major outer membrane proteins was performed according to the manufacturer's instructions. Briefly, 0.5 ml of urine was centrifuged at 16,000 × g for 10 min at 37°C followed by centrifugation at 8,000 × g for 5 min. The supernatant was decanted, and the pellet was resuspended in 0.2 ml of specimen diluent buffer. Twenty five microliters of amplification reagent was added to separate tubes, followed by the addition of 200 µl of oil reagent. Fifty microliters of processed specimen pipetted under the oil, and the tubes were incubated for 10 min at 95°C in a heating block. The tubes were cooled to 42°C, and 25 µl of enzyme reagent was added and the mixture was incubated for 1 h at 42°C. Twenty microliters of termination reagent was added, and the mixture was incubated for 10 min at 42°C. The probe was added and the tubes were incubated for 15 min at 60°C. The selection reagent was added and the tubes were incubated for 10 min at 60°C prior to the hybridization protection assay, which was performed according to the instructions in the manufacturer's package insert.

Data analysis. Variables and outcome predictors were recoded prior to analysis to indicate the absence or presence of urinary components. Both univariate and multivariate analyses were performed to determine which urinary components were associated with complete amplification inhibition. Univariate analysis was carried out by the continuity-corrected chi-square test. For multivariate analysis, forward logistic regression modeling was performed with SPSS software (version 7.0). Type I (alpha) error rate was set at 0.05 (two tailed for all analyses).

RESULTS

A total of 388 urine specimens were examined in the study; of these, 101 were positive for beta-human chorionic gonadotropin (beta-HCG). The number of urine specimens containing inhibitors for the three assays is shown in Table 1. A total of 27 urine specimens (7.0%) had inhibitors for PCR, 15 (3.9%) had inhibitors for LCR, and 46 (11.9%) had inhibitors for TMA. For PCR, 19 urine specimens had complete inhibi-

FIG. 1. Algorithm showing procedures used to study specimens containing inhibitors of PCR, LCR, and TMA. Complete Inhibition, signal below the cutoff of positivity for the test; Phenol-chloroform, nucleic acid precipitated overnight.

Fresh urine → Spike → LCR → Complete inhibition

PCR

Storing O/N

Phenol-chloroform extraction

TMA

Stored O/N

-70°C

L7R 1:1

1:10

1:1

1:4

1:10

1:4

1:10

95°C

4°C

37°C

2,000 × g

10 min

L2 434 was propagated in McCoy cells, and elementary bodies (EBs) were resuspended in phosphate-buffered saline and counted by direct fluorescent-antibody (DFA) staining with monoclonal antibodies specific for major outer membrane proteins (Syva Microtrak, San Jose, Calif.). A serial dilution of antibody (DFA) staining with monoclonal antibodies specific for major outer membrane proteins was performed according to the manufacturer's instructions. Briefly, 0.5 ml of urine was centrifuged at 16,000 × g for 10 min at 37°C followed by centrifugation at 8,000 × g for 5 min. The supernatant was decanted, and the pellet was resuspended in 0.2 ml of specimen diluent buffer. Twenty five microliters of amplification reagent was added to separate tubes, followed by the addition of 200 µl of oil reagent. Fifty microliters of processed specimen pipetted under the oil, and the tubes were incubated for 10 min at 95°C in a heating block. The tubes were cooled to 42°C, and 25 µl of enzyme reagent was added and the mixture was incubated for 1 h at 42°C. Twenty microliters of termination reagent was added, and the mixture was incubated for 10 min at 42°C. The probe was added and the tubes were incubated for 15 min at 60°C. The selection reagent was added and the tubes were incubated for 10 min at 60°C prior to the hybridization protection assay, which was performed according to the instructions in the manufacturer's package insert.

Data analysis. Variables and outcome predictors were recoded prior to analysis to indicate the absence or presence of urinary components. Both univariate and multivariate analyses were performed to determine which urinary components were associated with complete amplification inhibition. Univariate analysis was carried out by the continuity-corrected chi-square test. For multivariate analysis, forward logistic regression modeling was performed with SPSS software (version 7.0). Type I (alpha) error rate was set at 0.05 (two tailed for all analyses).

RESULTS

A total of 388 urine specimens were examined in the study; of these, 101 were positive for beta-human chorionic gonadotropin (beta-HCG). The number of urine specimens containing inhibitors for the three assays is shown in Table 1. A total of 27 urine specimens (7.0%) had inhibitors for PCR, 15 (3.9%) had inhibitors for LCR, and 46 (11.9%) had inhibitors for TMA. For PCR, 19 urine specimens had complete inhibi-
ory activity, as defined by a reduction in the signal to a level below the manufacturer’s cutoff, and 8 additional urine specimens had detectable or partial inhibitory activity, as defined by at least a 20% reduction in the signal. Ten urine specimens completely inhibited the LCR and 5 additional urine specimens partially inhibited the LCR. For TMA, 29 urine specimens had complete inhibitory activity and 17 specimens had partial inhibitory activity. The percentage of urine specimens from pregnant women with complete inhibitory activity was 11.9% (12/101) versus 5.2% (6/120) for nonpregnant women. For TMA, 7.7% (3/38) of urine specimens had complete inhibitory activity and 2.1% (2/94) had partial inhibitory activity. The percentage of urine specimens from pregnant women with complete inhibitory activity was 11.9% (12/101) versus 5.2% (6/120) for nonpregnant women. For TMA, 7.7% (3/38) of urine specimens had complete inhibitory activity and 2.1% (2/94) had partial inhibitory activity.

The results of a univariate analysis of urine parameters associated with complete inhibition for PCR, LCR, and TMA are presented in Table 2. PCR inhibition was significantly associated (P < 0.05) with the presence of hemoglobin, beta-HCG, crystals, and bacteria. The presence of glucose and nitrates was statistically associated (P < 0.05) with LCR inhibition, while the presence of hemoglobin, protein, ketones, nitrates, crystals, and bacteria was associated (P < 0.05) with TMA inhibition. When multivariate analysis was performed to determine which substances were associated with inhibition, logistic regression modeling revealed that hemoglobin (odds ratio [OR], 3.29; P = 0.004), nitrates (OR, 3.57; P = 0.025), and crystals (OR, 3.59; P = 0.025) were associated with inhibition, and for LCR only nitrates were significantly associated with inhibition (OR, 14.36; P = 0.011).

The effects of storage at different temperatures and dilution of the urine on the inhibitory activity are indicated in Table 4. An insufficient volume of 5 urine specimens for TMA and 1 urine specimen for LCR left 24 and 9 urine specimens, respectively, for inhibitor removal studies. Storage overnight at 4°C removed inhibitory substances from 8 of 19 (42.1%) specimens for PCR, 5 of 9 (55.5%) specimens for LCR, and 19 of 24 (79.1%) specimens for TMA. Storage at −70°C similarly removed inhibitory substances from 11 of 19 (57.9%) specimens for PCR, 4 of 9 (44.4%) specimens for LCR, and 19 of 24 (79.1%) specimens for TMA. PCR inhibitors were removed further by dilution to 1:4 (after storage at 4 or −70°C) for 73.6% (14 of 19) of the specimens, and further dilution to 1:10 increased the proportion to 84.2% (16 of 19). Thus, 3 of 19 specimens resisted PCR inhibitor removal after storage and dilution. Dilution of specimens with inhibitors of TMA increased the numbers rendered noninhibitory from 19 to 22, leaving 2 of 24 persistently inhibitory urine specimens. Dilutions removed all inhibitory activity for LCR. Phenol-chloroform extraction removed the inhibitors from all urine specimens.

Because the AMPLICOR CT/NG had its own internal control, we were able to compare its ability to identify urine specimens containing PCR inhibitors. The AMPLICOR internal control detected 13 (3.4%) urine specimens that had inhibitory activity, while the exogenous DNA spike method detected 19 (4.9%) specimens that had completely inhibitory activity and an additional 8 specimens that had partial inhibitory activity.

### Table 1. Urine specimens from pregnant and nonpregnant women showing complete or partial inhibition for PCR, LCR, or TMA tests

<table>
<thead>
<tr>
<th>Group</th>
<th>PCR Complete</th>
<th>Partial</th>
<th>Total</th>
<th>LCR Complete</th>
<th>Partial</th>
<th>Total</th>
<th>TMA Complete</th>
<th>Partial</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregnant (n = 101)</td>
<td>10 (9.9)</td>
<td>2 (1.9)</td>
<td>12 (11.9)</td>
<td>1 (1.0)</td>
<td>2 (2.0)</td>
<td>3 (2.9)</td>
<td>7 (6.9)</td>
<td>5 (5.0)</td>
<td>12 (11.9)</td>
</tr>
<tr>
<td>Nonpregnant (n = 287)</td>
<td>9 (3.1)</td>
<td>6 (2.1)</td>
<td>15 (5.2)</td>
<td>9 (3.1)</td>
<td>5 (1.0)</td>
<td>12 (4.2)</td>
<td>22 (7.7)</td>
<td>12 (4.1)</td>
<td>34 (11.8)</td>
</tr>
<tr>
<td>Total (n = 388)</td>
<td>19 (4.9)</td>
<td>8 (2.1)</td>
<td>27 (7.0)</td>
<td>10 (2.6)</td>
<td>5 (1.3)</td>
<td>15 (3.9)</td>
<td>29 (7.5)</td>
<td>17 (4.4)</td>
<td>46 (11.9)</td>
</tr>
</tbody>
</table>

* Complete inhibition was defined as a reduction in the signal to a level below the cutoff for positivity in each assay; partial inhibition was defined as greater than 20% but less than 100% of the signal achieved by the positive control spike.

### Table 2. Univariate analysis of urinary substances associated with complete inhibition for PCR, LCR, or TMA

<table>
<thead>
<tr>
<th>Inhibitory substance</th>
<th>PCR No. (%) of inhibitory specimens</th>
<th>LCR No. (%) of inhibitory specimens</th>
<th>TMA No. (%) of inhibitory specimens</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Present</td>
<td>Absent</td>
<td>Total</td>
</tr>
<tr>
<td>Glucose</td>
<td>0/19</td>
<td>20/369</td>
<td>0.297</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>1/19</td>
<td>98/369</td>
<td>&lt;0.05*</td>
</tr>
<tr>
<td>Protein</td>
<td>4/19</td>
<td>81/369</td>
<td>0.926</td>
</tr>
<tr>
<td>Ketone</td>
<td>2/19</td>
<td>30/369</td>
<td>0.711</td>
</tr>
<tr>
<td>Nitrates</td>
<td>2/19</td>
<td>23/369</td>
<td>0.457</td>
</tr>
<tr>
<td>beta-HCG</td>
<td>12/19</td>
<td>89/369</td>
<td>&lt;0.001***</td>
</tr>
<tr>
<td>Crystals</td>
<td>12/19</td>
<td>116/369</td>
<td>&lt;0.01**</td>
</tr>
<tr>
<td>Bacteria</td>
<td>15/19</td>
<td>206/369</td>
<td>&lt;0.05*</td>
</tr>
</tbody>
</table>

* Six other substances not statistically related were leukocytes, urates, oxalates, phosphates, casts, and yeasts.

Statistically significant differences are indicated as follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001.
VOL. 36, 1998

URINARY INHIBITORS OF TESTS FOR C. TRACHOMATIS

TABLE 3. Multivariate analysis of urinary substances associated with complete inhibition of amplification by PCR, LCR, and TMA assays

<table>
<thead>
<tr>
<th>Assay</th>
<th>Inhibitory substance</th>
<th>OR</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMA</td>
<td>Hemoglobin</td>
<td>3.29</td>
<td>0.004</td>
</tr>
<tr>
<td></td>
<td>Nitrates</td>
<td>3.57</td>
<td>0.025</td>
</tr>
<tr>
<td></td>
<td>Crystals</td>
<td>3.18</td>
<td>0.005</td>
</tr>
<tr>
<td>PCR</td>
<td>beta-HCG</td>
<td>3.43</td>
<td>0.038</td>
</tr>
<tr>
<td></td>
<td>Crystals</td>
<td>3.59</td>
<td>0.025</td>
</tr>
<tr>
<td>LCR</td>
<td>Nitrates</td>
<td>14.36</td>
<td>0.011</td>
</tr>
</tbody>
</table>

* Substances associated with inhibition were determined by logistic regression analysis.

DISCUSSION

In this study of 388 urine specimens from women, the prevalence of urine specimens containing detectable inhibitors was 7.0% for PCR, 3.9% for LCR, and 11.9% for TMA. When complete inhibition was considered, the prevalence of inhibitory urine specimens was 4.9% for PCR, 2.6% for LCR, and 7.5% for TMA. Inhibition rates were similar for urine specimens from pregnant and nonpregnant women for LCR (4.2 versus 2.9%) and TMA (11.8 versus 11.9%). For PCR, however, the proportion of inhibitory urine specimens from pregnant women was 11.9%, whereas the proportion from nonpregnant women was 5.2% (P = 0.038). The mechanism of PCR inhibition associated with beta-HCG is unknown.

In a letter recently published by Jensen et al. (9), the investigators reported that 15 of 1,136 urine specimens (1.3%) from pregnant patients possibly had plasmid LCR inhibitors because these samples were negative by the LCX test but positive by other tests such as DFA analysis, enzyme immunoassay, major outer membrane protein or LCR, but they did not perform inhibitor studies. As described in another letter (13), the investigators assumed a rate of 3% inhibition for cervical swabs from prostitutes because of differences seen between NAA testing and other assays, but they did not perform studies for LCR inhibitors. Berg et al. (1) used DNA spiking and reported the presence of LCR inhibitors in 10 of 382 (2.6%) urine specimens from men attending a sexually transmitted disease clinic. Our LCR inhibition rate of 3.9%, which was achieved with a DNA spike equivalent to 1 EB, was similar to the previously reported rates presented above and particularly the 2.6% rate reported by Berg et al. (1), who used the LCX-positive control DNA equivalent to 50 inclusion-forming units.

PCR has been shown by others to have reduced sensitivity due to inhibitors (7, 11, 18, 19). Those studies have shown that inhibitors could be removed by dilution, freezing and thawing, heating, or prolonged storage of the sample. Roche Molecular Systems has developed an internal amplification control to identify specimens containing PCR inhibitors. The internal control can be incorporated into both the manual AMPLICOR CT/NG test and the semiautomated COBAS AMPLICOR system (14). Specimens yielding a negative result for the internal control are interpreted as inhibitory or nonamplifiable and thus are not reported as negative, thereby reducing the number of false-negative results. In our study the internal control detected 13 inhibitory specimens, while our exogenous DNA spike method detected 19 inhibitory specimens. The discrepancies observed between the kit’s internal control and our DNA spike for female urine specimens may be due to weakly inhibitory specimens for which the results were below the limit of detection for the Roche internal control. The kit internal control has a slightly higher number of target molecules (20 copies of plasmid) compared with the one EB that we used in our spike. In this study 15 specimens were positive for C. trachomatis by either PCR, LCR, or TMA, but none of these urine specimens contained inhibitors by either the DNA spike method or the Roche internal control method. For this reason, the efficiency of the internal control for identifying specimens with false-negative results could not be determined. Further studies with larger numbers of specimens will be required to determine if the use of an internal amplification control is a cost-effective approach for monitoring amplification inhibition.

To our knowledge this is the first study to attempt to correlate inhibition of NAA with substances found in urine. Nitrates were associated with LCR inhibition, beta-HCG and crystals were associated with PCR inhibition, and hemoglobin, nitrates, and crystals were associated with TMA inhibition. These results, however, do not establish a direct causal relationship between the implicated urinary substance and inhibition since a small number of urine specimens (n = 22) which had lost their inhibitory activity after storage were found on subsequent urinalysis to have retained the implicated inhibitory substance. Not all urine specimens were restested by urinalysis. For the 11 urine specimens that were inhibitory in two NAA assays, we attempted to determine whether one assay was more sensitive to a single substance, i.e., nitrates. One urine specimen containing nitrates and beta-HCG was inhibitory for TMA and PCR but not for LCR. Since nitrates were associated with inhibition for TMA (OR, 3.57) and LCR (OR, 14.36) by multivariate logistic regression analysis and this urine specimen was not inhibitory for LCR, the existence of a complex interaction between urinary substances resulting in amplification inhibition is suggested.

Overnight storage at either 4 or −70°C removed 42.1 and 55.5% of the inhibitors for PCR and LCR, respectively, and 79.1% of the inhibitors for TMA. Storage at either 4 or −70°C combined with dilution to 1:10 removed all of the inhibitors for LCR and most of the inhibitors for PCR (16 of 19) and TMA (22 of 24). Phenol-chloroform extraction removed inhibitors from all urine specimens. The mechanism(s) involved in the removal of amplification inhibitors following storage at 4 or −70°C and dilution remain unknown. Dilution alone may remove inhibitory activity. Alternatively, freezing and thawing may destroy labile inhibitory molecules or release additional target DNA molecules by disrupting microbial cells more efficiently. This might account for the increased sensitivity ob-

TABLE 4. Removal of amplification inhibitors by various treatments

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Dilution</th>
<th>PCR (%)</th>
<th>LCR (%)</th>
<th>TMA (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4°C overnight</td>
<td>1:1</td>
<td>8/19 (42.1)</td>
<td>5/9 (55.5)</td>
<td>19/24 (79.1)</td>
</tr>
<tr>
<td></td>
<td>1:4</td>
<td>14/19 (73.6)</td>
<td>7/9 (77.7)</td>
<td>22/24 (91.6)</td>
</tr>
<tr>
<td></td>
<td>1:10</td>
<td>16/19 (84.2)</td>
<td>9/9 (100)</td>
<td>22/24 (91.6)</td>
</tr>
<tr>
<td>−70°C overnight</td>
<td>1:1</td>
<td>11/19 (57.9)</td>
<td>4/9 (44.4)</td>
<td>19/24 (79.1)</td>
</tr>
<tr>
<td></td>
<td>1:4</td>
<td>14/19 (73.6)</td>
<td>9/9 (100)</td>
<td>22/24 (91.6)</td>
</tr>
<tr>
<td></td>
<td>1:10</td>
<td>16/19 (84.2)</td>
<td>9/9 (100)</td>
<td>22/24 (91.6)</td>
</tr>
<tr>
<td>Phenol-chloroform</td>
<td>1:1</td>
<td>19/19 (100)</td>
<td>9/9 (100)</td>
<td>24/24 (100)</td>
</tr>
<tr>
<td></td>
<td>1:4</td>
<td>19/19 (100)</td>
<td>9/9 (100)</td>
<td>24/24 (100)</td>
</tr>
<tr>
<td></td>
<td>1:10</td>
<td>19/19 (100)</td>
<td>9/9 (100)</td>
<td>24/24 (100)</td>
</tr>
</tbody>
</table>
served with the AMPLICOR CT/NG test when frozen specimens are assayed (16). Alternatively, freezing and thawing may act directly on labile proteinaceous inhibitors, inducing conformational changes and the subsequent loss of inhibitory activity. Salts, especially those containing divalent cations, particularly Mg$^{2+}$ ions, which have a significant effect on the activity of Taq polymerase, could explain the inhibitory activity of urinary crystals for PCR and LCR.

In summary, we have demonstrated a variable rate of inhibition for C. trachomatis NAA assays ranging from 3.9 to 11.9%. An elevated rate of inhibition related to pregnancy was found for PCR but not LCR or TMA. In this study none of the inhibitory urine specimens were from infected patients, and the 15 urine specimens with endogenous C. trachomatis nucleic acid had no inhibitors. Most but not all of the inhibition was removed by storage and dilution, and only five urine specimens (three for PCR and two for TMA) required phenol-chloroform extraction to remove the inhibitors. The use of storage and dilution of urine specimens should be considered to reduce the inhibitory effects of urine specimens, especially those to be tested by PCR or TMA. Alternatively, tests most significantly affected by urinary inhibitors may benefit from the use of an internal positive control which gives a signal just above the positive cutoff value. More studies are warranted to determine whether urinary factors could be predictive of NAA inhibition.

ACKNOWLEDGMENTS

We thank Roche Molecular Systems, Abbott Diagnostics, and Gen-Probe for supplying the Chlamydia kits and Michael St. Pierre, Loraine Vaillancourt, and Janet Spenser for collecting urine specimens for this study.

REFERENCES


